0.0218  0.002 (7.39%)		02-29 15:53
Open: 0.0203 High: 0.022025 Volume: 310,872		Pre. Close: 0.0203 Low: 0.02 Market Cap: 1(M)

Short term
Mid term
Targets	6-month :	0.01	1-year :	0.02
Resists	First :	0.01	Second :	0.02
Pivot price	0.01
Supports	First :	0.01	Second :	0
MAs	MA(5) :	0.01	MA(20) :	0.01
	MA(100) :	0.02	MA(250) :	0.31
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	2.1	D(3) :	10.5
RSI	RSI(14): 39.7
52-week	High :	3.46	Low :	0.01

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ BXRX ] has closed above bottom band by 26.3%. Bollinger Bands are 72.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 91 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.01 - 0.01	0.01 - 0.01
Low:	0.01 - 0.01	0.01 - 0.01
Close:	0.01 - 0.01	0.01 - 0.01

Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMBA, which is in phase I clinical trial; BX3000, an NMBA reversal agent; and Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.

Wed, 28 Feb 2024
Baudax Bio files for Chapter 11 bankruptcy protection By Investing.com - Investing.com

Thu, 28 Sep 2023
Why Is Baudax Bio (BXRX) Stock Up 75% Today? - InvestorPlace

Mon, 03 Jul 2023
Baudax Bio (BXRX) Up 125% on Acquiring TeraImmune - Yahoo Finance

Fri, 30 Jun 2023
Baudax Bio Soars on Snapping Up Cell Therapy Developer TeraImmune - TipRanks.com - TipRanks

Fri, 30 Jun 2023
Why Is Baudax Bio (BXRX) Stock Up 130% Today? - InvestorPlace

Thu, 27 Apr 2023
Why Is Baudax Bio (BXRX) Stock Down 52% Today? - InvestorPlace

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	44 (M)
Held by Insiders	4.359e+007 (%)
Held by Institutions	0 (%)
Shares Short	36 (K)
Shares Short P.Month	0 (K)

EPS	-3.476e+007
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-2 %
Return on Assets (ttm)	759.8 %
Return on Equity (ttm)	-115 %
Qtrly Rev. Growth	1.27e+006 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	-94.2 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-14 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	-0.02

Dividend	0
Forward Dividend	474290
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.